Deladex

Quick links to important sections

Deladex

Method of action: Antivirals For Systemic Use

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deladex

Property Description
Active ingredient Didanosine (ddI)
Form Extended-release capsules, Oral solution
Pharmacological class Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Common use Management of HIV infection
Origin Synthetic (purine nucleoside analogue)

Deladex: Identity and Classification as an Antiretroviral

Deladex is a prescription-only pharmaceutical agent utilized in the treatment of Human Immunodeficiency Virus (HIV) infection. The active chemical substance in Deladex is Didanosine, which is often identified by the abbreviation ddI.

Didanosine is classified within the pharmacological class of Nucleoside Reverse Transcriptase Inhibitors (NRTIs), placing it among the foundational antiretroviral agents used for HIV management. Didanosine works to slow the spread of HIV in the body. Its general therapeutic purpose is to slow the progression of HIV infection by achieving a decrease in viral load, a strategy clinically recognized for maintaining patient immune health.

Composition, Origin, and Available Forms of Didanosine

Didanosine is a chemically manufactured, synthetic purine nucleoside analogue, meaning it is designed in a laboratory to mimic a naturally occurring nucleoside in the body. It is a single-ingredient product, containing only Didanosine as the active compound.

Didanosine is administered through the oral route and is available in two key dosage forms: extended-release capsules and an oral solution. The availability of the liquid formulation is a distinguishing factor that provides critical flexibility for patient groups, such as children or those unable to swallow solid medications. The capsules are designed for simplified, long-term adherence in controlling HIV infection, reflecting the evolution of this first generation antiretroviral agent.

Regulatory References

  1. National Library of Medicine (MedlinePlus) confirms

What side effects are possible with Deladex?

Possible side effects and safety information

Didanosine (Deladex) is associated with officially documented adverse reactions that range from common occurrences to serious, life-threatening events, as detailed in regulatory prescribing information.


Serious and Life-Threatening Risks

The most critical safety concerns are potentially fatal pancreatitis, lactic acidosis, and severe hepatomegaly with steatosis (liver enlargement with fat accumulation). These systemic events are emphasized in official labeling. Serious adverse reactions also include non-cirrhotic portal hypertension associated with long-term use, optic neuritis, and the potential for Immune Reconstitution Inflammatory Syndrome (IRIS) upon initiation of combination antiretroviral therapy.


Common Adverse Reactions and Affected Systems

The most frequent adverse reactions, documented to occur at a frequency of greater than 10% in adults, primarily affect the nervous and gastrointestinal systems. These include peripheral neurologic symptoms (neuropathy), headache, diarrhea, nausea, vomiting, and rash.

System-Organ Class Common Adverse Reactions (>10%)
Nervous System Peripheral neuropathy, Headache
Gastrointestinal Diarrhea, Nausea, Vomiting
Skin Rash

Population-Specific Safety Considerations

Official labeling defines specific increased risks for certain patient groups. Elderly patients and patients with renal impairment are at increased risk for pancreatitis. An increased risk of fatal lactic acidosis has been reported for pregnant women when Didanosine is used in combination with stavudine. Coadministration of Didanosine with stavudine is contraindicated due to the significantly increased risk of serious adverse events.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Deladex

Overdose Scope

Feature Official Regulatory Statement (Didanosine)
Documented Manifestations Symptoms include severe gastrointestinal distress (nausea, vomiting, diarrhea), extreme weakness, and peripheral neuropathy (numbness, tingling, or pain in the hands or feet).
Physiological Systems Affected Hepatic, Pancreatic, Central Nervous System, and Metabolic System.
Dose/Exposure Factors Risk of Lactic Acidosis is associated with prolonged nucleoside exposure.
Population-Specific Notes Patients with renal impairment or advanced HIV infection (especially the elderly) face increased risk of pancreatitis. Women and individuals with obesity are identified as specific risk factors for Lactic Acidosis.

Overdose Classifications (High-Level)

Classification Regulatory Statement
Severity Classification Overdose may be associated with life-threatening events, specifically Lactic Acidosis and fatal hepatic events.
Regulatory Basis Based on official labeling from the FDA and NIH.
Overdose-Context Constraints Management is restricted to symptomatic and supportive treatment, as no specific antidote is known; hemodialysis can be used as a procedural measure.

Official Overdose Statements

  • Immediate medical attention is required due to the documented risk of life-threatening organ toxicity, including pancreatitis and severe hepatic failure.
  • Urgent activation of emergency services is mandated for explicit triggers such as collapse, seizure, trouble breathing, or inability to be awakened.
  • Contacting the Poison Control Helpline is a specified action in the event of a suspected overdose.

Connection to the overall overdose profile:

Regulatory documents define the Deladex overdose profile by highlighting the severe, potentially fatal risk of metabolic (Lactic Acidosis) and organ toxicity, which necessitates rapid medical intervention. This documented severity dictates the mandatory guidance that individuals must seek immediate medical attention when experiencing specific, listed trigger symptoms. The management protocol is officially restricted to supportive care.

Therapeutic Uses of Deladex

What Deladex Treats: Main Uses and Benefits

Deladex is commonly used to help manage symptoms related to heightened physiological activity across several therapeutic domains. This medication may be part of symptomatic management in situations involving certain distressing symptoms. It is applied to treat a range of conditions, including various forms of arthritis, severe allergic reactions, asthma, and certain blood or hormone disorders.


Symptom Management and Therapeutic Support

Deladex is relevant for easing the symptoms related to physical discomfort, such as swelling, pain, redness, or heat. It is used for managing pronounced manifestations of allergic or immune origin, including widespread itching and rashes. In clinical settings where the body struggles to produce necessary natural hormones, Deladex is applied for supportive therapy to help ease the symptoms associated with hormonal deficiency.

This medication is often used during phases when symptoms become more noticeable, helping to maintain a sense of stability and ease the overall symptom burden. It is commonly used across conditions presenting with acute episodes where additional symptomatic support is needed.


Quick Fact: Relief for Symptom Clusters

Deladex is commonly used across conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is appropriate.

Regulatory References

  1. NIH MedlinePlus overview on Dexamethasone

Eligibility and Restrictions for Use

Population Eligibility and Regulatory Restrictions

Deladex (Didanosine) is subject to strict eligibility rules documented in official regulatory labeling. Use is absolutely contraindicated in patients with a known hypersensitivity to the drug or any of its components. Co-administration with certain other antiretroviral agents, specifically Stavudine (d4T), Allopurinol, or Ribavirin, is also prohibited due to the high risk of severe, life-threatening events.

Use is subject to conditional restrictions based on the patient's physiological status. Individuals with impaired kidney function require dosage changes and may be ineligible for certain formulations if impairment is severe. Patients with a history of pancreatitis or worsening liver disease must use the medicine with extreme caution, and discontinuation is required if non-cirrhotic portal hypertension develops.

Regarding age, use is not established for infants under 2 weeks old. For pregnant individuals, the official label specifically contraindicates the combination of Deladex with Stavudine. Breastfeeding during treatment is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Deladex (Didanosine) documents several pharmacokinetic and pharmacodynamic interaction patterns, resulting in mandatory restrictions and specific co-administration rules.

Formal Contraindications and Exposure Risk

Co-administration is formally contraindicated with certain other medicinal products due to the risk of severe, life-threatening toxicities. This includes combination with Stavudine (d4T) due to additive toxicity risk and with Allopurinol or Ribavirin due to the unsafe increase in the systemic exposure of Didanosine. The combination with Tenofovir Disoproxil Fumarate (TDF) results in a significant 40% to 60% increase in Didanosine plasma levels, a clinically significant pharmacokinetic interaction that raises the risk of dose-related adverse events.

Timing and Substance Constraints

The absorption of Deladex is highly sensitive to the presence of food; administration must occur on an empty stomach to ensure adequate bioavailability. Furthermore, regulatory agencies mandate separation in dosing time for Deladex with certain medications. This includes specific antiretroviral agents (e.g., Atazanavir/Ritonavir, Darunavir/Ritonavir) and metal-containing antacids or supplements (e.g., iron salts), due to pH-dependent absorption interference. Use of alcohol is also documented as increasing the risk of serious toxicities such as pancreatitis and hepatic damage.

Population Considerations

The increased exposure risk from pharmacokinetic interactions, such as those with Tenofovir, is heightened in patients with impaired renal function, requiring regulatory caution in this specific population.

Mechanism of Action

How Deladex Works: Mechanism of Action

Deladex acts as a selective agonist on alpha-2 adrenergic receptors (α2-AR), primarily within the Central Nervous System (CNS). This binding activates an inhibitory G-protein cascade that suppresses noradrenergic signaling, particularly in the Locus Coeruleus. The resulting marked decrease in overall sympathetic outflow from the CNS constitutes the foundational mechanism. This cascade produces the physiological consequence of decreased vigilance and diminished responsiveness to external stimuli.

In the spinal cord dorsal horn, α2-AR activation locally inhibits the presynaptic release of pain-transmitting neurotransmitters like Substance P. This molecular event effectively interrupts the central propagation of afferent pain signals, resulting in the physiological consequence of analgesia (attenuation of pain signaling). The concurrent reduction in sympathetic tone, combined with direct peripheral α2-AR effects, modulates cardiovascular systems, which includes the resulting bradycardia (decreased heart rate) and hypotension (decreased blood pressure).

Dosage and Administration Information

Deladex is administered exclusively via the oral route, utilizing either the delayed-release capsules or the reconstituted oral solution. The determination of the daily dose is based on both the formulation used and the patient's characteristics. For adults, the dosing regimen for the delayed-release capsules is weight-dependent, with individuals weighing 60 kilograms or more typically receiving a 400 mg dose once daily, and those under 60 kilograms typically receiving 250 mg once daily. The capsule form is designed for a once-daily schedule.

A mandatory procedural condition for administration is that Deladex must be taken on an empty stomach. This is defined as administering the medicine at least 30 minutes before or 2 hours after the consumption of food. Furthermore, the delayed-release capsules must be swallowed whole; they should not be crushed, broken, or chewed to ensure the integrity of the controlled drug release properties.

A critical requirement for patient management involves dose modification for individuals with impaired kidney function. The dose must be reduced based on the patient’s estimated creatinine clearance (CrCl) to prevent excessive drug exposure. For the pediatric population, the dosing protocol employs a calculation based on body surface area rather than simple weight thresholds. Deladex is used as part of a long-term, continuous therapy and requires consistent administration at regular intervals.

Recent Clinical Evidence

Research evidence / Overview of Studies for Deladex (Didanosine)

Evidence for Use in Managing HIV-1 Infection

Didanosine, the active component of Deladex, was studied for its role as a component used in combination treatment for Human Immunodeficiency Virus (HIV) infection. The initial and most comprehensive evidence was evaluated in Randomized Controlled Trials (RCTs). These RCTs often focused on comparing regimens containing Didanosine against those using other initial antiretroviral agents or placebo, particularly in individuals who had not received prior HIV medication (treatment-naïve).

In these studies, researchers primarily monitored surrogate markers of disease activity. The main outcomes examined included measurements of HIV-1 RNA levels in the blood, often referred to as viral load, and counts of CD4+ T-lymphocytes, which reflect immune status. Further meta-analyses aggregated data from these shorter-term trials to describe long-term outcomes and patterns in the studied groups.

Evaluation of Antiretroviral Combinations and Comparators

Early research explored its use in dual-therapy regimens, often combined with Zidovudine. These comparative studies explored whether the use of Didanosine as a component was associated with different patterns of disease progression. These studies focused on outcomes monitoring physiological strain or stress and the time to new clinical events (such as AIDS-defining illnesses).

Studies described group patterns related to these clinical outcomes. Research highlights changes measured during the study period related to virologic control and immune status when Didanosine was used in combination with other agents. It is important to remember that these findings describe group patterns, not personal outcomes, and reflect the specific conditions under which the trials were conducted.

What is Still Uncertain or Currently Under Research

There are several areas where data remain insufficient or where evidence is limited regarding the use of Didanosine. The data for long-term outcomes in patients over 65 years of age is not well-characterized, meaning there is limited information in this specific group. Furthermore, while studies monitored the emergence of specific viral resistance mutations, the full clinical relevance of these resistance changes has not been fully established in all contexts. Finally, early key research used older formulations (buffered tablets), and while bioequivalence studies exist, the main body of evidence reflects trials conducted under specific historical conditions.

Frequently Asked Questions (FAQ)

Common questions about Deladex (FAQ)

Q: Does Deladex have common side effects that usually go away?

A: Official product information indicates that some side effects are potentially reversible. For instance, the numbness or tingling in the hands and feet (peripheral neuropathy) may improve if the medicine is stopped or if the dose is adjusted.

Q: Are the side effects of Deladex different for older adults?

A: Regulatory documents state that older adults may have an increased likelihood of age-related kidney problems. Since Deladex dosage is often tied to kidney function, caution and dose adjustments may be factors considered in this population.

Q: Are there any specific foods or drinks I should avoid while using Deladex?

A: Regulatory documents state the medicine is administered on an empty stomach, which is typically defined as at least 30 minutes before or 2 hours after food. Official warnings also state that consuming alcohol may increase the risk of serious side effects, such as inflammation of the pancreas (pancreatitis).

Q: Why do some people need to take Deladex for a long time?

A: Deladex is classified as an antiretroviral medication used as part of a combination regimen. It is indicated for the chronic treatment of HIV-1 infection. The long-term, continuous therapy is used to help suppress the virus and delay the progression of the disease.

Q: Can Deladex be used by women who are planning to become pregnant?

A: The official label documents severe risks, including fatal lactic acidosis, when Deladex is used in combination with another specific medicine (stavudine) during pregnancy. Because of potential risks to the fetus and infant, it is important that individuals are aware of this information, particularly when planning for pregnancy.

Q: Is Deladex safe to use if I have kidney issues?

A: Official labeling advises caution for individuals with impaired kidney function. This is because the medicine is cleared from the body more slowly, which can lead to increased exposure. Regulatory documents indicate that dose adjustments are made based on kidney function (creatinine clearance).

Q: Can people with liver problems use Deladex?

A: The product information documents serious liver concerns, including severe liver enlargement and non-cirrhotic portal hypertension. Official documentation notes that caution is a factor for individuals who have known risk factors for liver disease.

Q: Why is Deladex sometimes prescribed in combination with other medicines?

A: Deladex is officially prescribed as a component of a larger combination regimen. This approach is used to maximize the suppression of the HIV virus and to help prevent the virus from becoming resistant to the medicines over time.

Q: What is the general duration of effect for a single dose of Deladex?

A: Deladex is formulated for a once-daily schedule. This administration frequency is designed to maintain a consistent concentration of the active ingredient in the body for approximately 24 hours.

Q: What is the official classification of Deladex (e.g., controlled substance)?

A: Deladex is classified as a Nucleoside Reverse Transcriptase Inhibitor (NRTI). This classification means it belongs to the group of foundational antiretroviral medicines used for managing HIV infection.

Q: If I feel better, can I stop taking Deladex on my own?

A: Official product use information describes the requirement for continuous, consistent administration. Skipping doses may lead to an increase in the HIV viral load in the blood. This lack of consistency can also increase the risk of the virus developing resistance to the medication.

Q: Why does the official leaflet mention specific types of machinery or tasks to avoid?

A: Warnings related to driving or operating machinery are included because the official label reports side effects affecting the Central Nervous System (CNS). These reported effects include dizziness, headaches, and lethargy (tiredness), which can impair mental alertness.

Q: Can Deladex make my current condition worse initially?

A: Regulatory warnings mention the risk of Immune Reconstitution Inflammatory Syndrome (IRIS) when starting combination antiretroviral therapy. IRIS is a known complication where the recovering immune system may temporarily cause a worsening of symptoms from an existing or previously unrecognized infection.

Q: I'm using an herbal product. Could it interact with Deladex?

A: The official product label includes explicit warnings regarding potential interactions with other medications and dietary supplements. Since herbal products may contain ingredients that interfere with absorption or increase side effect risks, the label indicates caution is necessary.

Q: Does Deladex need to be taken at a specific time of day?

A: Official regulatory information describes a once-daily regimen taken at regular intervals. While a specific time of day (like morning or night) is not mandated, maintaining consistency with the dosing schedule is required to ensure steady levels of the medicine in the blood.

Q: Is it normal to feel a bit drowsy when first starting Deladex?

A: Official side effect listings include lethargy, which is a state of tiredness or fatigue, as a central nervous system-related effect. Other reported effects are dizziness and headaches.

Q: Is Deladex meant to treat symptoms or the underlying condition?

A: Deladex is primarily indicated for the treatment of the underlying HIV-1 infection. Its role is to act as an antiretroviral to slow down the production and spread of the virus in the body.

Q: What kind of monitoring is typically done when a person starts Deladex?

A: Regulatory documents describe the requirement for consistent patient management and monitoring. This typically includes regular blood tests to check vital organ functions, such as the kidney, liver, and pancreas, and also the white blood cell count.

Q: What happens if I miss a scheduled time to take Deladex?

A: Missing doses may lead to an increase in the HIV viral load in the blood. According to regulatory documents, a lack of consistent dosing may also increase the risk of the virus becoming resistant to the medicine, potentially limiting future treatment options.

Q: Does Deladex cause weight changes?

A: Official adverse event reports indicate that changes in body fat distribution have been observed. This can manifest as the loss of fat (lipoatrophy) from the face and limbs, or a gain of fat around the back and waist.

Q: I heard Deladex can affect sleep. Is this true?

A: Yes, difficulty with sleeping, clinically known as insomnia, is a reported side effect of Deladex. This is listed among the common adverse events in official regulatory documents.

Q: Is it necessary to have certain tests done before starting Deladex?

A: Official warnings state that baseline blood tests are generally required before starting the medicine. These tests are used to check the current function of the liver and kidneys to ensure the medicine is properly dosed and to monitor for potential adverse effects.

Q: Is Deladex available in a generic version?

A: Yes, the active ingredient in Deladex is Didanosine. Since Didanosine is the internationally recognized generic name for the drug, generic formulations are typically available.

Q: What are the documented effects of Deladex on children?

A: Official product information details risks for the pediatric population. These documented effects include risks associated with mitochondrial dysfunction, which can result in temporary blood disorders or rare neurological disorders that may appear later.

Q: Can Deladex affect my mood?

A: Yes, regulatory documents list central nervous system side effects such as irritability and restlessness. These are reported adverse events that can affect a person's mood or behavior.

How should Deladex be stored and disposed of?

How to Store and Dispose of Deladex: Official Regulatory Information

Official regulatory documents define specific requirements for the storage, protection, and disposal of Deladex.

Mandatory Storage Conditions

Deladex must be stored at controlled room temperature (e.g., 20°C to 25°C) and requires protection from both light and moisture. The product should not be frozen or stored above the specified maximum temperature. It must remain in the original, tightly closed container and be kept strictly out of the sight and reach of children.

Stability and Disposal Rules

If the container is opened or the product is reconstituted, a limited in-use stability period applies, and any unused portion must be discarded after this defined time. Expired or unused Deladex must be disposed of according to official instructions, such as drug take-back programs. The medication must not be flushed down a toilet or disposed of in a drain, and disposal should avoid release into the aquatic environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deladex found in:

A-Z Index: